Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avapritinib - Blueprint Medicines

Next Previous
X
Search
Drug Profile

Avapritinib - Blueprint Medicines

Alternative Names: AYVAKIT; AYVAKYT; BLU-285; CS 3007; Taijihua

Latest Information Update: 22 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Blueprint Medicines
  • Developer Blueprint Medicines; CStone Pharmaceuticals; Neopharm Ltd
  • Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Pyrazoles; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules; Triazines
  • Mechanism of Action Platelet-derived growth factor alpha receptor antagonists; Proto-oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastrointestinal stromal tumours; Systemic mastocytosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastrointestinal stromal tumours; Systemic mastocytosis
  • Phase II Haematological malignancies
  • Phase I/II Solid tumours

Most Recent Events

  • 13 Jun 2024 Updated efficacy and adverse events data from the phase II PATHFINDER trial in Systemic mastocytosis presented at the 29th Congress of the European Haematology Association (EHA-2024)
  • 30 May 2024 Updated efficacy data the phase II PATHFINDER trial in Systemic mastocytosis released by Blueprint Medicines
  • 12 Apr 2024 Blueprint Medicines Corporation completes a phase I drug-drug interaction trial in Solid tumours (Second-line therapy or greater, Late-stage disease) in USA (PO, Tablet) (NCT04908176)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top